{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:37:38Z","timestamp":1791488258046,"version":"4.3.4"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":49,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The purpose of this study was to evaluate the efficacy and safety of low- to medium-dose (160\u00a0mg\/W or 80\u00a0mg\/W) telitacicept in adults at high risk of progression IgA nephropathy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a single-center retrospective study. The study included adults with high risk progression of IgA nephropathy who were treated with telitacicept between November 2022 and April 2024 and followed for at least 24 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In this study of 11 patients, telitacicept significantly reduced proteinuria by 64.38% (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and increased eGFR by 23.18% (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.005) at week 24. Both the 80\u00a0mg and 160\u00a0mg dose groups demonstrated significant reductions in proteinuria (68.67% and 59.23%, respectively, both\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and urinary RBC counts. The overall response rate was 90.91%. Telitacicept demonstrated a favorable safety profile, with only mild injection-site reactions reported (18.2%) and no serious adverse events.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this real-world study, low- to medium-dose of telitacicept combined with conventional therapy showed rapid onset efficacy and safety for treating high-risk progressive IgA patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12882-025-04708-w","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T16:35:54Z","timestamp":1765989354000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and safety of low- to medium-dose telitacicept in adults with high-risk progressive IgA nephropathy: a retrospective real-world study"],"prefix":"10.1186","volume":"27","author":[{"given":"Juan","family":"Pei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuhua","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruihong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejuan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijing","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hengyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leping","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"issue":"1","key":"4708_CR1","doi-asserted-by":"publisher","first-page":"10994","DOI":"10.1038\/s41598-020-67910-w","volume":"10","author":"R Hu","year":"2020","unstructured":"Hu R, Quan S, Wang Y, Zhou Y, Zhang Y, Liu L, et al. Spectrum of biopsy proven renal diseases in central china: a 10-year retrospective study based on 34,630 cases. Sci Rep. 2020;10(1):10994.","journal-title":"Sci Rep"},{"issue":"5","key":"4708_CR2","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s00281-021-00890-9","volume":"43","author":"J Floege","year":"2021","unstructured":"Floege J, Barratt J. IgA nephropathy: a perspective for 2021. Semin Immunopathol. 2021;43(5):625\u20136.","journal-title":"Semin Immunopathol"},{"issue":"3","key":"4708_CR3","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1053\/j.ajkd.2019.02.016","volume":"74","author":"T Chen","year":"2019","unstructured":"Chen T, Li X, Li Y, Xia E, Qin Y, Liang S, et al. Prediction and risk stratification of kidney outcomes in IgA nephropathy. Am J Kidney Dis. 2019;74(3):300\u20139.","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"4708_CR4","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2025.04.004","volume":"108","author":"BH Rovin","year":"2025","unstructured":"Rovin BH, Barratt J, Cook HT, Noronha IL, Reich HN, Suzuki Y, et al. KDIGO 2025 clinical practice guideline for the management of Immunoglobulin A nephropathy (IgAN) and Immunoglobulin A vasculitis (IgAV). Kidney Int. 2025;108(4):S1\u201371.","journal-title":"Kidney Int"},{"issue":"10","key":"4708_CR5","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1681\/ASN.2011050464","volume":"22","author":"H Suzuki","year":"2011","unstructured":"Suzuki H, Kiryluk K, Novak J, Moldoveanu Z, Herr AB, Renfrow MB, et al. The pathophysiology of IgA nephropathy. J Am Soc Nephrol. 2011;22(10):1795\u2013803.","journal-title":"J Am Soc Nephrol"},{"key":"4708_CR6","doi-asserted-by":"crossref","unstructured":"Cao Y, Lu G, Chen X, Chen X, Guo N, Li W. BAFF is involved in the pathogenesis of IgA nephropathy by activating the TRAF6\/NF-\u03baB signaling pathway in glomerular mesangial cells. Mol Med Rep. 2019.","DOI":"10.3892\/mmr.2019.10870"},{"issue":"11","key":"4708_CR7","doi-asserted-by":"publisher","first-page":"e3099","DOI":"10.1097\/MD.0000000000003099","volume":"95","author":"YL Zhai","year":"2016","unstructured":"Zhai YL, Zhu L, Shi SF, Liu LJ, Lv JC, Zhang H. Increased APRIL expression induces IgA1 aberrant glycosylation in IgA nephropathy. Medicine. 2016;95(11):e3099.","journal-title":"Medicine"},{"issue":"3","key":"4708_CR8","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.3892\/mmr.2014.2359","volume":"10","author":"W LI","year":"2014","unstructured":"LI W, PENG X, LIU Y, LIU H, LIU F. TLR9 and BAFF: their expression in patients with IgA nephropathy. Mol Med Rep. 2014;10(3):1469\u201374.","journal-title":"Mol Med Rep"},{"issue":"6","key":"4708_CR9","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1080\/08923973.2021.1973493","volume":"43","author":"F Shi","year":"2021","unstructured":"Shi F, Xue R, Zhou X, Shen P, Wang S, Yang Y. Telitacicept as a BLyS\/APRIL dual inhibitor for autoimmune disease. Immunopharmacol Immunotoxicol. 2021;43(6):666\u201373.","journal-title":"Immunopharmacol Immunotoxicol"},{"issue":"3","key":"4708_CR10","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.ekir.2022.12.014","volume":"8","author":"J Lv","year":"2023","unstructured":"Lv J, Liu L, Hao C, Li G, Fu P, Xing G, et al. Randomized phase 2 trial of telitacicept in patients with IgA nephropathy with persistent proteinuria. Kidney Int Rep. 2023;8(3):499\u2013506.","journal-title":"Kidney Int Rep"},{"issue":"4","key":"4708_CR11","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1093\/ndt\/gfr527","volume":"27","author":"W Le","year":"2012","unstructured":"Le W, Liang S, Hu Y, Deng K, Bao H, Zeng C, et al. Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population. Nephrol Dialysis Transplantation. 2012;27(4):1479\u201385.","journal-title":"Nephrol Dialysis Transplantation"},{"issue":"2","key":"4708_CR12","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1053\/j.ajkd.2023.12.016","volume":"84","author":"C Tang","year":"2024","unstructured":"Tang C, Chen P, Si FL, Lv JC, Shi SF, Zhou XJ, et al. Time-Varying proteinuria and progression of IgA nephropathy: A cohort study. Am J Kidney Dis. 2024;84(2):170\u2013e1781.","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"4708_CR13","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s00281-021-00888-3","volume":"43","author":"J Floege","year":"2021","unstructured":"Floege J, Rauen T, Tang SCW. Current treatment of IgA nephropathy. Semin Immunopathol. 2021;43(5):717\u201328.","journal-title":"Semin Immunopathol"},{"issue":"14","key":"4708_CR14","first-page":"1671","volume":"81","author":"S Dhillon","year":"2021","unstructured":"Dhillon S, Telitacicept. First Approval Drugs. 2021;81(14):1671\u20135.","journal-title":"First Approval Drugs"},{"key":"4708_CR15","doi-asserted-by":"crossref","unstructured":"Gao S, Yang C, Huang B, Yang L, Lu L, Yang H, et al. Comparative efficacy and safety of different recommended doses of telitacicept in patients with systemic lupus erythematosus in China: a systematic review and meta-analysis. Frontiers in Immunology. Front Immunol. 2024;15.","DOI":"10.3389\/fimmu.2024.1472292"},{"issue":"3","key":"4708_CR16","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.ekir.2024.11.1363","volume":"10","author":"J Liu","year":"2025","unstructured":"Liu J, Han X, Jiang X, Gao X, Li G, Fang X, et al. Efficacy and safety of telitacicept as an Add-On therapy for refractory Immunoglobulin A nephropathy or Immunoglobulin A vasculitis nephropathy in children. Kidney Int Rep. 2025;10(3):940\u20133.","journal-title":"Kidney Int Rep"},{"key":"4708_CR17","doi-asserted-by":"crossref","unstructured":"Weng Q, Ouyang Y, Chen Z, Jin Y, Xu J, Liu J, et al. Efficacy and safety of telitacicept in IgA nephropathy: real-world study outcomes. Clin Kidney J. 2025;18(6).","DOI":"10.1093\/ckj\/sfaf154"},{"issue":"1\u20132","key":"4708_CR18","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1159\/000529650","volume":"54","author":"Z Huang","year":"2023","unstructured":"Huang Z, Zhang J, Chen B, Li D, You X, Zhou Y, et al. Clinical significance of persistent hematuria degrees in primary IgA nephropathy: a propensity score-matched analysis of a 10-Year follow-up cohort. Am J Nephrol. 2023;54(1\u20132):62\u201373.","journal-title":"Am J Nephrol"},{"key":"4708_CR19","doi-asserted-by":"crossref","unstructured":"Yu Gzhen, Guo L, Dong J, feng, Shi S fang, Liu LJ, Wang JW, et al. Persistent hematuria and kidney disease progression in IgA nephropathy: a cohort study. Am J Kidney Dis. 2020;76(1):90\u20139.","DOI":"10.1053\/j.ajkd.2019.11.008"},{"issue":"1","key":"4708_CR20","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1080\/0886022X.2021.1879852","volume":"43","author":"P He","year":"2021","unstructured":"He P, Wang H, Huang C, He L. Hematuria was a high risk for renal progression and ESRD in Immunoglobulin a nephropathy: a systematic review and meta-analysis. Ren Fail. 2021;43(1):488\u201399.","journal-title":"Ren Fail"},{"key":"4708_CR21","doi-asserted-by":"crossref","unstructured":"Wang M, Ma J, Yao L, Fan Y. Efficacy and safety of telitacicept, a BLyS\/APRIL dual inhibitor, in the treatment of IgA nephropathy: a retrospective case-control study. Clin Kidney J. 2024;17(10).","DOI":"10.1093\/ckj\/sfae285"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04708-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-025-04708-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04708-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T11:48:31Z","timestamp":1770205711000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12882-025-04708-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4708"],"URL":"https:\/\/doi.org\/10.1186\/s12882-025-04708-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7621514\/v1","asserted-by":"object"}]},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]},"assertion":[{"value":"15 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of The First Affiliated Hospital of Xiamen University ((IRB approval No. 186 [2025]\u200b), with the requirement for informed consent waived in accordance with the retrospective observational study design. Ethics approval was applied in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"92"}}